Siponimod for treating secondary progressive multiple sclerosis: Final appraisal document

DRAFT guidance recommends use within marketing authorisation, as an option for treating secondary progressive MS with evidence of active disease (i.e. relapses or imaging features of inflammatory activity) in adults only if company provides it according to commercial arrangement.

Source:

National Institute for Health and Care Excellence